Oncotarget

Research Papers:

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study

Qi Yao, Hongsen Zhang, Bin Xiong _ and Chuansheng Zheng

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:79012-79022. https://doi.org/10.18632/oncotarget.20745

Metrics: PDF 1055 views  |   HTML 1527 views  |   ?  


Abstract

Qi Yao1, Hongsen Zhang1, Bin Xiong1 and Chuansheng Zheng1

1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China

Correspondence to:

Bin Xiong, email: herrxiong@126.com

Keywords: sorafenib, hepatocellular carcinoma (HCC), transcatheter arterial chemoembolization (TACE), portal vein invasion, combined therapy

Received: December 07, 2016     Accepted: August 07, 2017     Published: September 08, 2017

ABSTRACT

Purpose: This study aims to investigate the effect of sorafenib plus Transarterial Chemoembolization (TACE) treatment on inhibiting portal vein invasion in patients with intermediate stage HCC.

Materials and Methods: The consecutive medical records of patients with HCC were retrospectively analyzed from October 2009 to February 2015. The propensity score matching method was applied into group matching. The Kaplan-Meier method and the Log-Rank Test was used to estimate the median survival time, median time to progression and median time to portal vein invasion. Factors associated with survival benefits were identified by univariate and multivariate Cox-regression model analyses.

Results: Of 97 patients enrolled, 19 patients received TACE-sorafenib treatment and 78 patients received TACE treatment. During the follow-up period of 15 months, the median time to portal vein invasion was 14.2 months vs 8.77 months, respectively (p=0.073). And the analysis of the cox's proportional hazard model revealed that patients treated with TACE treatment alone would run greater risk of portal vein invasion compared with TACE-sorafenib treatment (hr=7.49, p=0.021). Early administration of sorafenib was associated with lower risk of portal vein invasion (p=0.021) according to the univariate analysis. Adverse events (AEs) identified in the combined group were mostly classified as Grades 1 and 2, and skin-related reactions and fatigue were the most common.

Conclusions: Sorafenib may could inhibit portal vein invasion of hepatoma carcinoma cells. Early administration of sorafenib may bring more survival benefits.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20745